

SIGNATURE PRIORITY

Institute for Data Science in Oncology

Unlocking the power of big data and AI

Like putting pieces of a puzzle together to reveal the full picture, MD Anderson Cancer Center amasses patient data paired with deep analyses to illuminate the future of cancer care. The challenge? How to collect and store this valuable information, scientifically interpret it, and then translate new data into a new therapy or cure.

We seek to decrypt data using state-of-the-art tools and techniques to find unseen patterns, to derive meaningful information, and to inform action and discovery. By revealing clues that hide deep within vast amounts of data, the Institute for Data Science in Oncology integrates the power of artificial intelligence and data science. With unparalleled scientific and clinical expertise, the institute transforms the patient experience, enhances quality of life and accelerates scientific breakthroughs in cancer care.

In patients with a cancer diagnosis, data-driven decisions can unlock a new dimension that comprises genomics, proteomics and 3D imaging. All this information, properly gathered and analyzed, can help us to deliver better, safer care and ultimately to unlock the mystery of cancer. When fully realized, the institute will be one of the single largest investments in oncology data science in history.

MISSION

Eliminate cancer in Texas, the nation and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public

5 THINGS TO KNOW ABOUT MD ANDERSON

- MD Anderson Cancer Center is ranked No. 1 in the nation for cancer care in U.S. News & World Report's "Best Hospitals" survey and has been named one of the nation's top two hospitals for cancer care since the survey began in 1990
- Saw 187,000 patients, completed 1.7 million outpatient visits and delivered \$346 million in uncompensated care in the past fiscal year
- Home to the world's largest cancer clinical trials program
- Invested \$1.3 billion in research in the past fiscal year
- Received 188 patents and tested 27 drugs that received Food and Drug Administration (FDA) approval in the past fiscal year

To learn more, visit MDAnderson.org/QuickFacts

